SG11202107389SA - Hexone glucokinase inhibitor and use thereof - Google Patents
Hexone glucokinase inhibitor and use thereofInfo
- Publication number
- SG11202107389SA SG11202107389SA SG11202107389SA SG11202107389SA SG11202107389SA SG 11202107389S A SG11202107389S A SG 11202107389SA SG 11202107389S A SG11202107389S A SG 11202107389SA SG 11202107389S A SG11202107389S A SG 11202107389SA SG 11202107389S A SG11202107389S A SG 11202107389SA
- Authority
- SG
- Singapore
- Prior art keywords
- hexone
- glucokinase inhibitor
- glucokinase
- inhibitor
- hexone glucokinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910085547 | 2019-01-29 | ||
| CN201910316417 | 2019-04-19 | ||
| CN201910985433 | 2019-10-17 | ||
| PCT/CN2020/073813 WO2020156445A1 (fr) | 2019-01-29 | 2020-01-22 | Inhibiteur de glycokinase hexanone et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202107389SA true SG11202107389SA (en) | 2021-08-30 |
Family
ID=71840269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202107389SA SG11202107389SA (en) | 2019-01-29 | 2020-01-22 | Hexone glucokinase inhibitor and use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220106299A1 (fr) |
| EP (1) | EP3919484B1 (fr) |
| JP (1) | JP7248255B2 (fr) |
| KR (1) | KR20210120080A (fr) |
| CN (2) | CN113412260B (fr) |
| AU (1) | AU2020214064B2 (fr) |
| CA (1) | CA3127130A1 (fr) |
| SG (1) | SG11202107389SA (fr) |
| WO (1) | WO2020156445A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI764467B (zh) * | 2019-12-24 | 2022-05-11 | 大陸商南京明德新藥研發有限公司 | 具有khk抑制作用的化合物 |
| GB202001856D0 (en) | 2020-02-11 | 2020-03-25 | Inorbit Therapeutics Ab | Compounds useful in inhibiting ketohexokinase and methods of making and using the same |
| EP4134366A4 (fr) * | 2020-04-20 | 2023-10-11 | Lg Chem, Ltd. | Dérivé de 3-azabicycloalkyle et composition pharmaceutique le contenant |
| CN113999212B (zh) * | 2020-07-28 | 2023-07-28 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂的盐、晶型及其用途 |
| CN112028839B (zh) * | 2020-09-30 | 2022-04-12 | 中国海洋大学 | 一种医药中间体环烷烃并嘧啶二酮化合物的合成方法 |
| CN116635377A (zh) | 2020-12-25 | 2023-08-22 | 四川海思科制药有限公司 | 己酮糖激酶抑制剂及其用途 |
| US20230079863A1 (en) * | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
| TWI833193B (zh) * | 2021-04-01 | 2024-02-21 | 南韓商Ｌｇ化學股份有限公司 | 二唑化合物及含彼的藥學組成物 |
| WO2022262841A1 (fr) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | Forme de sel et forme cristalline de composé spiro et son procédé de préparation |
| KR20230098069A (ko) * | 2021-12-24 | 2023-07-03 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2023151473A1 (fr) * | 2022-02-09 | 2023-08-17 | 上海研健新药研发有限公司 | Inhibiteur de khk, son procédé de préparation et son utilisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011078143A1 (fr) | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | Dérivés de pyrimidine et composition pharmaceutique les contenant |
| US8822447B2 (en) * | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| TW201206946A (en) | 2010-07-15 | 2012-02-16 | Bristol Myers Squibb Co | Compounds for the reduction of beta-amyloid production |
| TW201309655A (zh) * | 2011-01-28 | 2013-03-01 | 必治妥美雅史谷比公司 | 降低β－類澱粉生成之化合物 |
| US8871756B2 (en) * | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
| EA032081B1 (ru) | 2014-12-08 | 2019-04-30 | Янссен Сайенсиз Айрлэнд Юси | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) |
| WO2016142310A1 (fr) * | 2015-03-09 | 2016-09-15 | F. Hoffmann-La Roche Ag | Inhibiteurs de dlk tricycliques et utilisations associées |
| RS61896B1 (sr) * | 2015-12-29 | 2021-06-30 | Pfizer | Supstituisani 3-azabiciklo[3.1.0]heksani kao inhibitori ketoheksokinaze |
| TWI725266B (zh) * | 2016-12-19 | 2021-04-21 | 大陸商上海和譽生物醫藥科技有限公司 | Fgfr4抑制劑、其製備方法與藥學上的應用 |
| AR112027A1 (es) | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
| JP7301390B2 (ja) * | 2017-10-19 | 2023-07-03 | ジェイエス・イノファーム・（シャンハイ）・リミテッド | ヘテロ環式化合物、ヘテロ環式化合物を含む組成物、及びその使用方法 |
-
2020
- 2020-01-22 KR KR1020217027576A patent/KR20210120080A/ko not_active Application Discontinuation
- 2020-01-22 CA CA3127130A patent/CA3127130A1/fr active Pending
- 2020-01-22 AU AU2020214064A patent/AU2020214064B2/en active Active
- 2020-01-22 CN CN202080008816.2A patent/CN113412260B/zh active Active
- 2020-01-22 CN CN202210795995.XA patent/CN116023365A/zh active Pending
- 2020-01-22 SG SG11202107389SA patent/SG11202107389SA/en unknown
- 2020-01-22 WO PCT/CN2020/073813 patent/WO2020156445A1/fr active Application Filing
- 2020-01-22 EP EP20749439.4A patent/EP3919484B1/fr active Active
- 2020-01-22 US US17/426,675 patent/US20220106299A1/en active Pending
- 2020-01-22 JP JP2021543534A patent/JP7248255B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022518823A (ja) | 2022-03-16 |
| CN116023365A (zh) | 2023-04-28 |
| AU2020214064A1 (en) | 2021-08-05 |
| EP3919484A4 (fr) | 2021-12-08 |
| WO2020156445A1 (fr) | 2020-08-06 |
| CN113412260B (zh) | 2022-08-02 |
| CN113412260A (zh) | 2021-09-17 |
| KR20210120080A (ko) | 2021-10-06 |
| US20220106299A1 (en) | 2022-04-07 |
| EP3919484B1 (fr) | 2023-05-24 |
| CA3127130A1 (fr) | 2020-08-06 |
| EP3919484A1 (fr) | 2021-12-08 |
| AU2020214064B2 (en) | 2022-10-20 |
| JP7248255B2 (ja) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202107389SA (en) | Hexone glucokinase inhibitor and use thereof | |
| IL276095A (en) | gcn2 inhibitors and their uses | |
| IL282487A (en) | TYK2 inhibitors and their use | |
| IL276147A (en) | GCN2 inhibitors and uses thereof | |
| IL282998A (en) | Pyridzinone compounds and their uses | |
| IL282997A (en) | Pyridzinone compounds and their uses | |
| EP3572400C0 (fr) | Inhibiteur de l'ezh2 et son utilisation | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL282090A (en) | tyk2 inhibitors and uses thereof | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| IL272649A (en) | AHR inhibitors and their uses | |
| ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
| IL286622A (en) | prmt5 inhibitors and uses thereof | |
| IL285595A (en) | Spt5 inhibitors and uses thereof | |
| IL279276A (en) | ERK inhibitor and use thereof | |
| IL286485A (en) | pi4-kinase inhibitors and methods of using them | |
| IL280408A (en) | CDK inhibitors and uses thereof | |
| GB201906914D0 (en) | Substituted naphtahlene diimdes and their use | |
| GB201908884D0 (en) | Inhibitors and use | |
| HK1253249A1 (zh) | 新的5型磷酸二酯酶抑制劑及其應用 | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| EP3878841A4 (fr) | Inhibiteur d'indazole kinase et son utilisation |